Company Overview
XOMA Royalty Corporation functions as a biotech royalty aggregator that holds a portfolio of economic rights, generating future potential milestone and royalty payments from both commercial products and pre-commercial therapeutic candidates across the United States, Switzerland, the Asia Pacific, and Australia. Operating within the healthcare sector specifically as a biotechnology entity, the company leverages its asset-light model to monetize intellectual property without bearing the primary risks of drug development. The company's current market capitalization is listed as N/A, while its reported annual revenue stands at $52.15 million and its workforce consists of 14 employees. The absence of a disclosed market cap figure alongside a relatively small revenue base suggests the company operates as a specialized, niche player rather than a large-cap entity, positioning it as a micro-cap investment that derives value from high-margin royalty streams rather than traditional product sales volumes.
Financial Health
The company generated $52.15 million in revenue and reported a net income of $18.52 million, resulting in an EBITDA of $14.36 million, which highlights a significant disparity between top-line revenue and bottom-line profit due to substantial non-operating expenses or interest costs. While the net income figure is robust, the free cash flow stands at -$14,235,375, indicating that the company is currently burning cash, likely due to debt service obligations or reinvestment needs that exceed its operating cash generation. The gross margin is reported at 96.7%, reflecting the asset-light nature of the royalty model where costs of goods sold are minimal, while the operating margin sits at 15.9% and the profit margin reaches 60.8%, demonstrating that the majority of revenue is retained after operating expenses but before interest and taxes. On the balance sheet, the company holds $83.29 million in cash against $131.56 million in debt, resulting in a debt-to-equity ratio of 126.54, which signals a leveraged capital structure where debt obligations exceed the equity base. The current ratio of 3.37 indicates a strong liquidity position, meaning the company possesses more than three times the current assets required to cover its short-term liabilities. Return on equity is an impressive 34.1%, while return on assets is 2.9%, suggesting that management is highly effective at generating shareholder value per dollar of equity, even though the overall asset base generates a lower return due to the heavy debt load.
Valuation Assessment
The trailing twelve-month P/E ratio is 25.72, whereas the forward P/E is listed as N/A, implying that the market is currently pricing in a lack of consensus on future earnings growth or that forward estimates have not been established by analysts. The price-to-book ratio is 3.64, which indicates that the stock trades at a significant premium relative to its book value, a common characteristic for companies with valuable intangible assets like intellectual property portfolios. Price-to-sales and EV/EBITDA metrics are provided as N/A and 26.11 respectively, suggesting that traditional revenue-based valuation multiples are not currently applicable or disclosed, while the enterprise value multiple of 26.11 implies the market values the company's earnings power at a high multiple relative to its cash flow generation. The 52-week high is $30.00 and the 52-week low is $24.96, and without a specific current price provided in the facts, the trading range defines the volatility bounds within which the stock has moved over the past year. The beta is 0.83, indicating that the stock's price volatility is slightly lower than the broader market, suggesting it may be less sensitive to general market swings compared to the average stock.
Growth & Income
Revenue growth year-over-year is 57.9%, while earnings growth is listed as N/A, indicating that the top line is expanding rapidly, but the inability to calculate earnings growth suggests either a lack of historical data for comparison or a specific accounting nuance regarding the royalty income recognition. Because the earnings growth rate cannot be quantified against the revenue figure, one cannot definitively state if earnings are growing faster or slower, though the high revenue growth suggests expanding royalty collections. The dividend yield is 8.4%, while the payout ratio is N/A, meaning the company distributes a high percentage of its value to shareholders, but the sustainability of this payout cannot be fully assessed without a known earnings base for the ratio calculation. Given the high yield and the N/A status of the payout ratio, the company appears to be a high-income investment rather than a pure growth vehicle, reinvesting limited cash flow primarily to service debt rather than paying out dividends.